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OBJECTIVE — We examined the impact of adherence to the Alternative Healthy Eating
Index (AHEI), a set of dietary guidelines targeting major chronic diseases, on metabolic syn-
drome (MetS) reversion in a middle-aged population.
RESEARCH DESIGN AND METHODS — Analyses were carried out on the 339 par-
ticipants (28% women, mean age 56.4 years) from the Whitehall II study with MetS as deﬁned
bytheNationalCholesterolEducationProgramAdultTreatmentPanelIIIcriteria.Reversionwas
deﬁned as not having MetS after 5 years of follow-up (158 case subjects).
RESULTS — After controlling for potential confounders, adherence to AHEI was associated
with MetS reversion (odds ratio 1.88 [95% CI 1.04–3.41]), predominantly in participants with
central obesity and in those with high triglyceride.
CONCLUSIONS — Our ﬁndings support the beneﬁt of adherence to AHEI dietary guide-
lines for individuals with MetS, especially those with central obesity or high triglyceride levels.
Diabetes Care 33:2339–2341, 2010
T
he metabolic syndrome (MetS),
prevalence estimated at between 10
and 25% in adult populations
worldwide (1), is associated with an in-
creasedriskoftype2diabetesandcardio-
vascular diseases (CVDs). Lifestyle
modiﬁcation, such as increased physical
exercise (2) and diet therapies (3,4), may
have a beneﬁcial impact on MetS. We ex-
amined a set of dietary guidelines target-
ing major chronic diseases known as the
Alternative Healthy Eating Index (AHEI)
(5). Our goal was to examine whether ad-
herence to AHEI was associated with re-
versionoftheMetSovera5-yearperiodin
a middle-aged population.
RESEARCH DESIGN AND
METHODS— Data came from
phases 3 (1991–1993), 5 (1997–1999),
and 7 (2002–2004) of the Whitehall II
study of London-based ofﬁce workers
(6). From the 3,698 participants with
complete data on MetS at phases 3 and
5, diet and covariates at phase 5, and
MetS reversion between phases 5 and 7,
the339casesubjectswithMetSatphase
5 formed the study population for the
main analysis.
At each phase, MetS was deﬁned us-
ing the National Cholesterol Education
Program Adult Treatment Panel III crite-
ria (7). The deﬁnition of each MetS com-
ponentanddetailsofothermeasurements
are given in the footnote of Table 1 and
have been described previously (8). The
5-year reversion of MetS was deﬁned as
not having MetS at phase 7.
Dietary intake data were collected via
a validated 127-item food frequency
questionnaire (FFQ) (9–10) at both
phases 3 and 5. AHEI score (5) was cre-
ated by summing its nine component
scores (1/fruits, 2/vegetables, 3/ratio of
white to red meat, 4/trans fat, 5/ratio of
polyunsaturated to saturated fat, 6/total
ﬁber,7/nutsandsoy,8/alcoholconsump-
tion, and 9/long-term multivitamin use);
ahigherscorecorrespondedtogreaterad-
herence (online appendix Table A1,
availableathttp://care.diabetesjournals.org/
cgi/content/full/dc09-2200/DC1). We used
the AHEI measures in two ways: the
phase 5 score was used for the main
analysis, and the average AHEI score
across phases 3 and 5 was used to take
into account longer-term adherence to
AHEIinasubsidiaryanalysisonthe337
participants with complete dietary data
from phases 3 and 5. Levels of AHEI
adherence at phase 5 were comparable
to those reported in two large American
cohorts (5) (online appendix Table A2).
Logistic regression models examined
the association between tertiles of the
AHEI scores at phase 5 and reversion of
MetS and of its components at phase 7,
sequentially adjusted for age, sex, ethnic-
ity (White, non-White) and total energy
intake (kcal/day) (model 1) and addition-
ally for educational attainment (no aca-
demic qualiﬁcation, lower secondary,
higher secondary, university degree,
higher university degree), marital status
(married or cohabiting, living alone),
smoking (current, former, nonsmoker),
persistence of MetS at phase 5 (having
MetS at both phases 3 and 5), depressive
symptoms,andintensityofphysicalactiv-
ity(high,medium,low)(8)(model2).No
signiﬁcant interaction between AHEI
scores and covariates (including sex) was
observed. Analysis was conducted using
the SAS software, version 9.1 (SAS
Institute).
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pants with MetS at phase 5, 158 (46.6%)
recovered by phase 7. Characteristics of the
participants(asafunctionofMetSreversion
andAHEIcategory)areshowninonlineap-
pendix Tables A3 and A4. After controlling
for potential confounders, adherence to
AHEIwasassociatedwithincreasedoddsof
MetS reversion over the 5-year follow-up
(Table 1). This association was stronger
among participants with MetS at both
phases 3 and 5 (n of reversions/total n 
56/155, odds ratio 3.74 [95% CI 1.37–
10.2]).TheAHEI-to-MetSreversionassoci-
ation was particularly evident among
participantswithcentralobesityandamong
thosewithhightriglycerides(Table1).Fur-
thermore, adherence to AHEI was associ-
ated with a 5-year reversion of the high
triglyceridecomponent(n276/767,1.61
[1.12–2.33]) but the association with
reversion of central obesity did not reach
statistical signiﬁcance (n  75/481, 1.42
[0.75–2.68]). Analyses with average AHEI
score across phases 3 and 5 as the exposure
largely replicated these ﬁndings (online
appendix Table A5).
CONCLUSIONS— Inthepresentre-
port, we show that adherence to dietary
guidance for healthy eating, the AHEI, is
associated with reversion of the MetS in
a middle-aged population. Although
several studies have investigated the diet-
to-MetS prevalence and incidence rela-
tionships, the impact of diet on MetS
reversion has only been studied in two
clinical trials assessing adherence to the
Mediterranean diet in two Mediterranean
countries.Onetrialof180Italiansubjects
found the Mediterranean diet interven-
tion to lead to reversion of MetS (3), the
other larger trial (n  1,224, Spanish)
suggestedthattheobservedeffectwasdue
to the effect of nut supplements rather
than the Mediterranean diet as a whole
(4). Even though the clinical utility of
MetSasanindependentpredictorofCVD
has been challenged (11), our ﬁndings,
from a non-Mediterranean country, are
novel and strengthen evidence of the po-
tential impact of diet in countering in-
creasing levels of risk factors associated
with CVD and type 2 diabetes.
We observed a stronger impact of
AHEI on MetS reversion in participants
with central obesity and high triglycer-
ides. Among all baseline MetS case sub-
jects, AHEI was associated with reversion
of the high triglyceride component but
not the central obesity component. Thus,
reduction of visceral fat (12) leading to a
decrease in the ﬂux of free fatty acids and
increased insulin resistance—a key fea-
ture in MetS pathophysiology (13)—
seems an unlikely explanation for our
ﬁndings. However, further research is
needed to examine these and other plau-
sible mechanisms. These may include
counteracting oxidative stress (and
related insulin resistance) (14) via anti-
oxidants from fruits, vegetables, and
long-term multivitamin use and the low-
ering of high triglyceride levels—linked
to reduction of inﬂammation processes
involved in MetS (15)—as a result of in-
creased consumption of polyunsaturated
fat, nuts, and soy and a reduced con-
sumption of trans fat.
Limitations of this study include the
small sample size that does not fully rep-
resent the British population (6) and that
does not allow ethnic group substratiﬁca-
tion other than White or non-White,
thereby limiting the generalizability of
our ﬁndings; the lack of objective mea-
sureofphysicalactivity;andtheuseofthe
FFQ, recognized to be less precise than
diary questionnaires, to assess diet.
Despite these limitations, our ﬁnd-
ings emphasize the potential beneﬁts of
adherence to the dietary recommenda-
Table 1—Association between adherence to the AHEI and 5-year reversion of the MetS
Model 1* Model 2†
Total 339
Low AHEI score‡ 115 (48) 1.00 (reference) 1.00 (reference)
Intermediate AHEI score§ 111 (50) 1.20 (0.69–2.08) 1.15 (0.65–2.05)
High AHEI score 113 (60) 1.73 (0.99–3.02) 1.88 (1.04– 3.41)
P¶ 0.05 0.04
Subcohort with central obesity 212
Low AHEI score‡ 71 (25) 1.00 (reference) 1.00 (reference)
Intermediate AHEI score§ 76 (30) 1.34 (0.67–2.67) 1.29 (0.61–2.76)
High AHEI score 65 (33) 2.35 (1.12–4.96) 2.77 (1.19–6.44)
P¶ 0.025 0.02
Subcohort with high triglycerides 294
Low AHEI score‡ 103 (43) 1.00 (reference) 1.00 (reference)
Intermediate AHEI score§ 92 (38) 1.07 (0.58–1.94) 1.01 (0.54–1.89)
High AHEI score 99 (54) 1.92 (1.06–3.49) 1.94 (1.04–3.65)
P¶ 0.03 0.04
Subcohort with low HDL cholesterol 198
Low AHEI score‡ 65 (28) 1.00 (reference) 1.00 (reference)
Intermediate AHEI score§ 60 (27) 1.00 (0.47–2.12) 1.03 (0.45–2.36)
High AHEI score 73 (38) 1.37 (0.67–2.81) 1.58 (0.70–3.55)
P¶ 0.36 0.26
Subcohort with hypertension 279
Low AHEI score‡ 98 (45) 1.00 (reference) 1.00 (reference)
Intermediate AHEI score§ 90 (42) 1.09 (0.60–1.99) 1.08 (0.57–2.02)
High AHEI score 91 (48) 1.48 (0.80–2.73) 1.61 (0.84–3.08)
P¶ 0.21 0.15
Subcohort with high glucose 131
Low AHEI score‡ 39 (13) 1.00 (reference) 1.00 (reference)
Intermediate AHEI score§ 51 (22) 1.48 (0.59–3.70) 1.41 (0.51–3.89)
High AHEI score 41 (21) 2.08 (0.80–5.43) 2.52 (0.81–7.88)
P¶ 0.13 0.11
Data are n, number of participants (number of reversion cases), or odds ratio (95% CI) for MetS reversion.
MetSwasdeﬁnedusingtheNCEPdeﬁnition(7)basedonthepresenceofthreeormoreofthefollowing:waist
circumference(men102cm,women88cm),serumtriglycerides(1.7mmol/l),HDLcholesterol(men
1.04mmol/l,women1.29mmol/l),bloodpressure(130/85mmHgsystolicoverdiastolicpressure),
fastingglucose(6.1mmol/l),orpresenceoftype2diabetes.Waistcircumferencewastakenasthesmallest
circumference at or below the costal margin. Resting blood pressure was measured with the participant
seated using the Hawksley random zero sphygmomanometer (phases 3 and 5) and the OMRON HEM 907
(phase 7). Serum triglycerides, HDL cholesterol, and fasting blood glucose were analyzed as previously
described (8).*Model 1: adjusted for sex, age, ethnicity, and energy intake. †Model 2: model 1 additionally
adjusted for education, marital status, smoking habits, physical activity, persistence of MetS, and depressive
symptoms. ‡Low AHEI adherence: median (range), 39.5 (3.5–43.5). §Intermediate AHEI adherence: 50.5
(44.5–55.5). High AHEI adherence: 62.5 (56.5—76.5). ¶P value of the comparison between high vs. low
AHEI score.
Overall diet and reversion of metabolic syndrome
2340 DIABETES CARE, VOLUME 33, NUMBER 11, NOVEMBER 2010 care.diabetesjournals.orgtions of the AHEI in middle-aged individ-
uals with MetS, especially those with
central obesity or high triglyceride levels.
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